HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
"HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Kejal Jadhav
- Kelly L. Schoenbeck (ORCID: https://orcid.org/0000-0002-2408-6836)
- Islam Sadek (ORCID: https://orcid.org/0000-0002-1072-4585)
- Andrea Damon
- Kathryn E. Flynn (ORCID: https://orcid.org/0000-0002-4427-3583)
- David Wei (ORCID: https://orcid.org/0000-0002-0000-4533)
- Karen DeMairo (ORCID: https://orcid.org/0009-0008-0741-5010)
- Cristina Constantinescu
- Nisha C. Hazra (ORCID: https://orcid.org/0000-0002-1424-6525)
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Daisy Yang
- Gabriel Marquez
- Yan Meng (ORCID: https://orcid.org/0000-0002-0614-8968)
- Joan Clements (ORCID: https://orcid.org/0009-0006-4317-7553)
- Annie Guérin
- Jennifer Hiller
Institutions
- University of California, San Francisco (US)
- Medical College of Wisconsin (US)
- M. Alexander Nugent Consulting (United States) (US)
- Novartis (Ireland) (IE)
- Leukemia and Lymphoma Society (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7251
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00